Brantly, Mark L.

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine

Tuberous Sclerosis Complex ResearchVascular Malformations and Hemangiomas

Cited by 1,099

Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I

Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 549

Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α 1 -Antitrypsin: Interim Results

Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 335

Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 327

Human Treg responses allow sustained recombinant adeno-associated virus–mediated transgene expression

Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 169

Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation

Lee, J., Arisi, I., Puxeddu, E., Mramba, L. K., Amicosante, M., Swaisgood, C. M., Pallante, M., Brantly, M. L., Sköld, C. M., & Saltini, C. (2018) · PLOS ONE

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 69

Myeloid-derived suppressor cells are necessary for development of pulmonary hypertension

Bryant, A. J., Shenoy, V., Fu, C., Marek, G., Lorentsen, K. J., Herzog, E. L., Brantly, M. L., Avram, D., & Scott, E. W. (2018) · American Journal of Respiratory Cell and Molecular Biology

Pulmonary Hypertension Research and TreatmentsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 47

Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

Kuoch, H., Krotova, K., Graham, M. L., Brantly, M. L., & Aslanidi, G. (2023) · Biomedicines

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 5